Genmab
GMAB
#1345
Rank
$13.14 B
Marketcap
$20.62
Share price
0.81%
Change (1 day)
-36.49%
Change (1 year)

P/E ratio for Genmab (GMAB)

P/E ratio as of November 2024 (TTM): 20.3

According to Genmab's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.3246. At the end of 2022 the company had a P/E ratio of 36.4.

P/E ratio history for Genmab from 2009 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202236.4-33.9%
202155.151.51%
202036.4-16.91%
201943.8-0.59%
201844.0-23.45%
201757.5-0.95%
201658.1-16.22%
201569.39.26%
201463.4-36.03%
201399.1-1426.2%
2012-7.48180.52%
2011-2.66-75.13%
2010-10.7202.86%
2009-3.54

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.